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INTRODUCTION
Among various human cancers, lung cancer is the most
prevalent in Japan and elsewhere (1) and has a poor
prognosis (2). The major obstacle in the therapy of lung
cancer is the development of distant organ metastases,
which cause most of the cancer-related deaths. Since lung
cancer, even on the time of the early diagnosis, is frequently
associated with distant micrometastases, conventional
therapeutic modalities such as chemotherapy, radiation
therapy and surgical resection, are little effective in terms
of prolongation of the survival. For this, lot of research
work are being focused on the development of new
therapeutic modalities against lung cancer, particularly
against its metastatic spread.
In the recent years, there has been a considerable
interest in the role of macrolides as biological response
modifiers (3-5) and the possibility of using macrolides
such as erythromycin and clarythromycin (CAM) in the
treatment of cancer as an adjuvant to anticancer chemo-
therapy and/or radiation therapy is being explored. There
is a report showing the effects of erythromycin on
reducing the tumor load and prolonging the survival of
mice inoculated with different types of tumor cells (6).
Moreover, long term CAM treatment has also been
reported to have prolonged the survival of patients with
inoperable non-small cell lung cancer (7). However,
clinical effect of CAM on the survival periods of lung
cancer patients remains debatable because of the limited
numbers of patients evaluated. There is no study whether
these macrolides have any therapeutic effect on the
distant organ metastases of lung tumors, which accounts
for the maximum cancer-related deaths.
Recently, we have developed novel metastasis models
of non-small cell lung cancers in severe combined
immunodeficient (SCID) mice which lack T cells and
B cells (8 , 9). Human squamous cell lung carcinoma
RERF-LC-AI cells were found to develop distant metastases
into various organs such as liver, kidneys and lymph
nodes 6 to 8 weeks after their i.v. inoculation into the
NK-depleted SCID mice (8). On the other hand, human
lung adenocarcinoma PC-14 cells formed multiple
metastases predominantly in lungs and regional lymph
nodes, when inoculated i.v. into the SCID mice (9). We
also found that these models allowed us to study effect of
macrophage activating cytokine (i.e. macrophage colony
stimulating factor) on distant organ metastases of human
lung cancer (10). Macrolides such as erythromycin and
CAM are shown to stimulate and/or potentiate functions
of monocyte/macrophages in terms of cytokine productions
(4-6). In this study, we have examined the effect of CAM
on the metastasis of two different non-small cell human
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lung cancer in our SCID mouse models.
MATERIALS AND METHODS
Cell lines and cell culture
The human squamous cell lung carcinoma RERF-LC-AI
cells were kindly provided by Dr. M. Akiyama (Radiation
Effects Research Foundation, Hiroshima, Japan). The
human lung adenocarcinoma PC-14 cells were kindly
provided by Dr. N. Saijo (National Cancer Institute,
Tokyo, Japan). Human Burkitt lymphoma (Daudi) cell line
was obtained from American Type Culture Collection
(Rockville, MD). Cell cultures were maintained in RPMI
1640 (Nissui Pharmaceutical Co., Tokyo, Japan) supple-
mented with 10% heat-inactivated fetal bovine serum
(FBS) (Gibco, Grand Island, NY, USA) and gentamycin
(Schering-Plough, Osaka, Japan), designated as complete
RPMI-1640 (CRPMI), at 37℃ in a humidified atmosphere
of 5% CO2 in air. Growth inhibition assays were performed
when the cultured target cells were in the exponential
phase of growth.
Reagents
Clarythromycin (CAM) was kindly supplied by Taisho
pharmaceutical Co., (Tokyo, Japan). Gum arabic was from
Katayama Chemicals (Osaka, Japan). Recombinant human
IL-2 (specific activity, 1.14 x 107 U/mg protein) was kindly
provided by Takeda Pharmaceutical Co. (Osaka, Japan).
Anti-mouse IL-2 receptor β chain monoclonal antibody,
TM-β1 (IgG2b), was obtained as described previously
(11). None of these materials contained endotoxins, as
judged by Limulus amebocyte assay (Seikagaku Kogyo
Co., Tokyo, Japan : minimum detection level 0.1 ng/ml).
Models of experimental metastases of human lung cancer cells
For experimental production of metastases of squamous
cell lung carcinoma (RERF-LC-AI) cells, SCID mice were
injected i.p. with TM-β1 antibody (1 mg/0.3 ml PBS/
mouse) 2 days before tumor inoculation to deplete them
of NK cells, as described (8, 9). However, for experiments
with lung adenocarcinoma (PC-14) cells, SCID mice were
used without the injection of TM-β1 antibody, because
these cells formed metastatic colonies in the lungs of NK
cell-undepleted mice in our preliminary experiments. The
viable tumor cells suspended in 0.3 ml of PBS were
injected into a lateral tail vein. Mice were treated s.c. with
PBS, 5% gum arabic or CAM daily from day 7-41. They
were sacrificed on day 42 and number of metastatic
colonies were counted. Nodules more than 1 mm in
diameter in the lungs were counted with the aid of a
dissecting microscope.
In vitro growth inhibition assay
In vitro cell proliferation was measured by the MTT
[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide]
dye-reduction method (12). In brief, tumor cells were
seeded in 96-well tissue culture plates at a density of 5 x
103 cells/well. After incubating the cells overnight, drug
treatments were initiated. The cells were exposed to the
drugs for 72 hours, and then 50 µl of stock MTT solution
(5 mg/ml) was added to all wells. After two hour incu-
bation, the culture media were removed and 100 µl of
dimethyl sulfoxide (DMSO) was added to dissolve the
dark blue crystals. Absorbance was measured with a
microplate reader (Corona Electric, Ibaragi, Japan) at test
and reference wavelengths of 550 and 630nm, respectively.
Lymphokine-activated killer (LAK) cell cytotoxicity assay
LAK mediated cytotoxicity was assayed by measuring
51Cr release in a 4 h test as described previously (13).
Briefly, peripheral blood mononuclear cells (MNC) were
separated from the blood of healthy donors in lymphocyte
separation medium. MNC (1 x105/well) were incubated in
CRPMI with the IL-2 (100 U/ml) in presence or absence
of indicated concentration of CAM for 4 days. The cells
were washed and used as effectors, incubated with Daudi
cells labeled with 51Cr at effector target ratio (E : T) of
10 : 1. After incubation for 4 h, the radioactivities of the
supernatants were determined. Results are expressed
as percent cytotoxicity, calculated using the following
formula : (E-S/M-S) X 100 (where, E=experimental cpm,
S=spontaneous cpm and M=maximum cpm). the spon-
taneous release in different experiments ranged from 5 to
15% of the maximum release.
Statistical analysis
The statistical significance of differences between groups
was analyzed by Student's two-tailed t test.
RESULTS
Effect of CAM on the metastases of RERF-LC-AI cells in
NK-depleted SCID mice.
We examined the antimetastatic effect of s.c. administration
of CAM on the metastasis of human squamous cell lung
carcinoma RERF-LC-AI in NK cell-depleted SCID mice as
described in the materials and methods. As shown in
Table 1, RERF-LC-AI cells formed numerous metastases
in the liver and kidneys, with a few metastases in the
lymph nodes. No significant difference was observed in
the formation of metastases among the groups of mice
treated with PBS, gum arabic and CAM, indicating the
ineffectiveness of CAM to inhibit distant metastases in this
model. Macroscopically, no difference between untreated
and CAM-treated groups was seen in the sizes of
metastatic nodules (Fig.1).
Effect of CAM on the metastasis of PC-14 cells in SCID
mice with intact NK activity
Next, we examined therapeutic efficacy of CAM to
inhibit metastasis of PC-14 cells in SCID mice undepleted
of NK cells as described in the materials and methods.
CAM was injected s.c. daily from day 7-41.On day 42, the
formation of metastatic colonies in the lungs and lymph
nodes were examined. As shown in Fig.2, PC-14 cells
formed metastatic colonies in the lungs and lymph nodes
in SCID mice treated with CAM at 10 mg/kg, and the
number of colonies of CAM-treated mice were not signifi-
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cantly different from the control groups, i.e., mice treated
with PBS or gum arabic alone. Moreover, there was no
remarkable difference in the formation of pleural effusion
in the CAM-treated mice compared with the mice treated
with gum arabic or PBS alone (data not shown).
Effect of CAM on the proliferation of human lung cancer
cells in vitro
To examine if the failure of CAM to inhibit metastases
of human lung cancer cells in SCID mice was due to it's
ineffectiveness in controlling their proliferation, we treated
two human lung cancer cells with various concentrations
of CAM and assayed their proliferation in vitro. CAM at
concentrations less than 10 mg/ml were not effective in
inhibiting the cell proliferation of RERF-LC-AI (Fig.3 A)
Table 1. Metastasis of RERF-LC-AI cells in NK-cell deleted SCID mice treated with CAM
No. of metastatic colonies (Mean±SD)
Treatment No. of mice Liver Kidneys Lymph nodes
Experiment 1
PBS
Gum arabic
CAM (5 mg/kg)
CAM (10 mg/kg)
Experiment 2
PBS
Gum arabic
CAM (5 mg/kg)
CAM (10 mg/kg)
5
5
5
5
4
4
4
4
98.6±21.6
106.8±18.5
94.2±30.7
115.2±21.2
108.8±19.6
115.6±19.6
110.5±32.3
95.5±38.7
41.2± 5.7
41.8± 6.5
36.0±11.6
40.4± 8.4
32.1±10.7
31.8± 9.8
33.8± 8.7
30.8±11.5
9.8± 3.4
8.0± 3.8
8.0± 2.6
8.4± 4.3
15.6± 4.0
19.0± 5.0
15.3± 7.9
16.3±11.5
SCID mice were pretreated with TM-β1 (1 mg) for NK cell depletion, then RERF-LC-Al cells (1 x 106) were injected i.v. into the mice. These
mice were treated with PBS, 5% Gum arabic or CAM daily from day 7-41. Mice were sacrificed on day 42 and number of metastatic colonies
were counted.
Fig.1. Metastasis of human lung cancer cells in NK cell-depleted SCID mice treated or untreated with CAM. RERF-LC-AI cells were inoculated
into a tail vein of SCID mice pre-treated with TM-β1 antibody. Mice were injected s.c. with PBS, 5% gum arabic or CAM (5 mg/kg or 10 mg/kg)
from day 7-41, killed on day 42 and metastatic nodules were counted. Each treatment group consisted of five mice, representative three are
shown in the figure.
Fig.2. Metastasis of PC-14 cells in SCID mice treated with CAM.
PC-14 cells (1 x 106) were injected i.v. into SCID mice without TM-β1
treatment. These mice, in groups of five, were treated with PBS, 5%
gum arabic or CAM daily from day 7-41. Mice were sacrificed on day
42 and the number of metastatic colonies were counted.
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and PC-14 (Fig.3 B), while CAM at concentrations of
higher than 100 µg/ml was very toxic to the cells.
Augmentation by CAM of the IL-2-induced LAK activity
of MNC
In order to check if CAM could modulate the anti-tumor
function of the immune system, we studied the effect of
CAM on the LAK activity of MNC induced with IL-2. As
shown in Fig.4, MNC incubated with IL-2 in presence of 1
and 10 µg/ml CAM showed significantly enhanced LAK
activity compared with MNC incubated with IL-2 alone.
DISCUSSION
The purpose of this study was to examine therapeutic
effect of CAM on the metastasis of lung cancer cells in
SCID mice models. We observed that the treatment with
CAM did not have any effect on the metastasis of human
squamous cell lung carcinoma RERF-LC-AI (Table 1 and
Fig.1) and lung adenocarcinoma PC-14 in SCID mice
models (Fig.2).
Recently much attention has been paid to antitumor
effect of macrolides such as erythromycin and CAM,
because of several suggestive reports. For example,
erythromycin in the dose ranges of 1-10 mg/kg body weight
were reported to be effective in reducing the tumor volume
and prolonging the survival of mice bearing Ehrlich
ascites carcinoma and P388 leukemia (6). Particularly, a
recent finding (7) that oral administration of CAM resulted
in significant prolongation of survival of patients with
inoperable non-small cell lung cancer stimulated us to
examine whether CAM treatment could affect metastases
of human non-small cell lung cancer in SCID mouse
models, because we have established novel metastases
models of non-small cell lung cancer in SCID mice (8, 9).
First, in NK cell-depleted SCID mice, we examined
whether daily treatment with CAM at doses of 5 mg/kg/
day and 10 mg/kg/day, could eradicate the development
of established micrometastases of squamous cell lung
carcinoma (RERF-LC-AI). Although RERF-LC-AI cells
were highly metastatic to liver, kidneys and lymph nodes,
antimetastatic effects of CAM were not seen on the distant
metastases at all (Table 1). Next, we also examined
whether CAM treatment could affect formations of tumor
nodules in the lungs with malignant pleural effusion and
lymph node metastases in SCID mice with intact NK cell
activity. When the SCID mice were sacrificed 42 days after
i.v. inoculation of lung adenocarcinoma (PC-14), multiple
metastatic nodules could be seen in the lungs and lymph
nodes with malignant pleural effusions as reported
previously (9). CAM (10 mg/kg/day) when administered
on day 7-41 after i.v. inoculation of PC-14 cells did not have
any antitumor effect on tumor metastases in lungs and lymph
nodes (Fig.2). We also observed that daily treatments
with CAM did not affect neither the numbers nor the sizes
of metastatic nodules formed in both metastasis models of
squamous cell lung cancer (RERF-LC-AI) in SCID mice
(Fig.1). Thus, our present findings are not in accordance
with previous report by others. The reasons for this
discrepancy between our and other observations (7) may
be due to several differences such as tumor growing sites,
origins of tumor, host immunocompetence and treatment
Fig.3. Proliferation of lung cancer cells in presence of CAM in vitro. Human lung cancer cells RERF-LC-AI (A) and PC-14 (B) were incubated
in medium with different concentrations of CAM. After 72 h, the proliferation was evaluated by MTT assay as described in the materials and
methods. Values are mean±SD of triplicates.
Fig.4. Effect of CAM on the IL-2-induced LAK activity of MNC.
MNC were incubated in medium with IL-2 in presence of different
concentrations of CAM. After 4 days, cells were harvested and their
LAK activity was assayed against 51Cr-labeled Daudi cells as described
in the materials and methods. Values are mean±SD of one represen-
tative of two experiments done in triplicates.
* p value<0.05 vs. LAK induced with IL-2 alone.
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schedule. Since CAM was not toxic to lung cancer cells at
physiological doses (Fig.3), it seems that antitumor effect
of CAM, as observed by other investigators, may be
mediated through the anti-tumor activities of host.
Regarding effect of CAM on host defense mechanisms,
there are accumulating evidence suggesting it's function
as biological response modifier. For example, CAM were
reported to have a stimulatory effect on the production of
IL-1β, TNF-α and IL-4 by monocytes (4-6). The SCID mice
do have intact monocyte/macrophage populations, and
even if NK cells were depleted, human lung cancer cells
which had been genetically engineered to produce M-CSF
could not develop distant metastases into liver and lymph
nodes in the SCID mice (10). Since daily treatments with
CAM were not effective in the present study, it appears
that only monocytes/macrophages are not enough to
mediate anti-metastatic effect in vivo .
Other effector cells in the antitumor system like
cytotoxic T cells, NK cells, or lymphokine activated killer
(LAK) cells could be involved in mediating the anti-tumor
effect of CAM in vivo. Particularly, NK cells are known as
primary effector cells responsible for inhibition of cancer
dissemination (14, 15). To examine this possibility, we
cultured human blood MNC with IL-2 in the presence or
absence of CAM and measured their NK and LAK
activities. CAM alone did not augment NK activity, but it
caused significant increase in the LAK activity induced by
IL-2 (Fig.4). The mechanism of stimulation of LAK activity
by CAM is not clear at present. Nevertheless, it is possible
that the monocytes, upon activation by CAM, lead to the
stimulation of LAK activity, because cytokine-activated
monocytes are known to stimulate the IL-2 induced LAK
activity (13). Thus, no effect of CAM on NK activity in
vitro may account for the therapeutic failure of CAM in the
pulmonary and lymph node metastases of adenocarcinoma
PC-14 cells in SCID mice bearing intact NK cells.
In summary, the present study showed that CAM alone
did not have therapeutic effect on the growth and organ
metastasis of human non-small cell lung cancer cells in
SCID mouse models. Nevertheless, the present finding
does not rule out a possibility that CAM may mediate
antitumor effect in the immunocompetent host through
stimulation of immune T cells. Further studies are required
to explore this possibility, particularly in combination with
other biological response modifier (s).
ACKNOWLEDGMENTS
We are grateful to Prof. M. Miyasaka and Dr. T. Tanaka
for kindly supplying hybridoma cells producing TM-β1
antibody. This work was supported by Grants-in-aid for
Cancer Research from the Ministry of Education, Science,
Culture and Sports of Japan.
REFERENCES
1. Stanley K, Stjernsward J : Lung cancer ; A worldwide
health problem. Chest, 96 (suppl.1) : 1 S-5S, 1989
2. Paesmans M, Sculier JP, Libert P, Bureau G, Dabouis
G, Thiriaux J, Michel J, Van Cutsem O, Sergysels R,
Mommen P, Klastersky J : Prognostic factors for sur-
vival in advanced non-small-cell lung cancer : univariate
and multivariate analyses including recursive partitioning
and amalgamation algorithms in 1,052 patients. J Clin
Oncol 13 : 1221-1230, 1995
3. Bailly S, Pocidalo JJ, Fay M, Gougerot-Pocidalo MA :
Differential modulation of cytokine production by
macrolides : IL-6 production is increased by spiramicin
and erythromycin. Antimicrobial Agents and Chemo-
therapy 35 : 2016-2019, 1991
4. Katahira J, Kikuchi K, Shibata Y, Hasegawa H,
Totsuka K, Shimizu K : Kinetic studies on the effects
of macrolides on cytokine production. Chemotherapy
39 : 678-686, 1991
5. Kita E, Sawaki M, Nishikawa F, Mikasa K, Yagyu Y,
Takeuchi S, Yasui K, Narita N, Kashiba S : Enhanced
interleukin production after long-term administration
of erythromycin stearate. Pharmacology 41 : 177-183,
1990
6. Hamada K, Kita E, Sawaki M, Mikasa K, Narita N :
Antitumor effect of Erythromycin in mice. Chemo-
therapy 41 : 59-69, 1995
7. Teramoto S, Mikasa K, Sawaki M, Hamada K,
Konishi M, Maeda K, Sakamoto M, Tsujimoto M,
Mori K, Kita E, Narita N : Long-term clarythromycin
treatment for inoperable non-small cell lung cancer.
Jpn J Chemother 44 : 451-458, 1996
8. Yano S, Nishioka Y, Izumi K, Tsuruo T, Tanaka T,
Miyasaka M, Sone S : Novel metastasis model of
human lung cancer in SCID mice depleted of NK
cells. Int J Cancer 67 : 211-217, 1996
9. Yano S, Nokihara H, Hanibuchi M, Parajuli P,
Shinohara T, Kawano T, Sone S : Model of malignant
pleural effusion of human lung adenocarcinoma in
SCID mice. Oncol Res 9 : (in press), 1998
10. Yano S, Nishioka Y, Nokihara H, Sone S : Macrophage
colony-stimulating factor gene transduction into human
lung cancer cells differentially regulates metastasis
formations in various organ microenvironments of
natural killer cell-depleted SCID mice. Cancer Res
57 : 784-790, 1997
11. Tanaka T, Tsudo M, Karasuyama H, Kitamura F,
Kono T, Hatakeyama M, Taniguchi T, Miyasaka M :
A novel monoclonal antibody against murine IL-2
receptor b-chain : characterization of receptor expres-
sion in normal lymphoid cells and EL-4 cells. J
Immunol 147 : 2222-2228, 1991
12. Green LM, Reade JL, Ware CF : Rapid colorimetric
assay for cell viability : application to the quantitation
of cytotoxic and growth-inhibitory lymphokines. J
Immunol Methods 70 : 257-268, 1984
13. Sone S, Inamura N, Nii A, Ogura T : Heterogeneity of
human lymphokine (IL-2)-activated killer (LAK)
presursors and regulation of their LAK induction by
blood monocytes. Int J Cancer 42 : 428-434, 1990
14. Whiteside TL, Herberman RB : The role of natural
killer cells in immune surveillance of cancer. Curr
Opin Immunol 7 : 704-710, 1995
２０９The Journal of Medical Investigation Vol.44 1998
15. Timonen T : Natural killer cells : endothelial inter-
actions, migration, and target cell recognition. J Leuk
Biol 62 : 693-701, 1997
P. Parajuli et al. Effect of CAM on lung cancer metastases２１０
